ReviewJournal of controlled release : official journal of the Controlled Release Society2021
Development of nanoparticle-delivery systems for antiviral agents: A review.
Review in Journal of controlled release : official journal of the Controlled Release Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.
- Global research trend of Herpes simplex keratitis: a bibliometric analysis and visualization from 1941 to 2024.Frontiers in medicine · 2025Pooled it
- Nanoparticles for antiviral nucleotide analogs: approaches and analytical challenges.Journal of virology · 2026Review
- Detection of Ursid Gammaherpesvirus 2 in Asiatic Black Bears (Ursus thibetanus) With Keratoconjunctivitis.Veterinary ophthalmology · 2026Article
- Comparison of Peganum harmala L. leaves extract nanoformulations against herpes simplex virus type 1 guided by network pharmacology analysis.Scientific reports · 2025Article
- Curcumin and Acute Myeloid Leukemia: Synergistic Effects with Targeted Therapy.International journal of molecular sciences · 2025Review
- Development of a general anti-viral therapeutic using cholestosome technology to exploit inhibition of intracellular viral production.Biochemistry and biophysics reports · 2025Article
- Bovine Serum Albumin Nanoparticle-Mediated Delivery of Ribavirin and Mycophenolic Acid for Enhanced Antiviral Therapeutics.Viruses · 2025Article
- Preparation, and ex vivo and in vivo Characterization of Favipiravir-Loaded Aspasomes and Niosomes for Nose-to-Brain Administration.International journal of nanomedicine · 2025Article
- Overcoming Solubility Challenges: Self-emulsifying Systems for Enhancing the Delivery of Poorly Water-Soluble Antiviral Drugs.Pharmaceutical nanotechnology · 2025Review
- Zero-Order Kinetics Release of Lamivudine from Layer-by-Layer Coated Macromolecular Prodrug Particles.International journal of molecular sciences · 2024Article
- Revolutionizing Antiviral Therapeutics: Unveiling Innovative Approaches for Enhanced Drug Efficacy.International journal of nanomedicine · 2024Review
- Nanoformulation of the Broad-Spectrum Hydrophobic Antiviral Vacuolar ATPase Inhibitor Diphyllin in Human RecombinantInternational journal of nanomedicine · 2024Article
- Navigating Latency-Inducing Viral Infections: Therapeutic Targeting and Nanoparticle Utilization.Biomaterials research · 2024Review
- The shape-dependent inhibitory effect of rhein/silver nanocomposites on porcine reproductive and respiratory syndrome virus.Discover nano · 2023Article
- Enhanced Anti-Herpetic Activity of Valacyclovir Loaded in Sulfobutyl-ether-β-cyclodextrin-decorated Chitosan Nanodroplets.Microorganisms · 2023Article
- Plant Cell-Engineered Gold Nanoparticles Conjugated to Quercetin Inhibit SARS-CoV-2 and HSV-1 Entry.International journal of molecular sciences · 2023Article
- Optical properties of nanostructured antiviral and anticancer drugs.RSC advances · 2023Article
- Polydopamine-based nanomedicines for efficient antiviral and secondary injury protection therapy.Science advances · 2023Article
- Antiviral Peptides Delivered by Chitosan-Based Nanoparticles to Neutralize SARS-CoV-2 and HCoV-OC43.Pharmaceutics · 2023Article
- Advances in Antiviral Delivery Systems and Chitosan-Based Polymeric and Nanoparticulate Antivirals and Antiviral Carriers.Viruses · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic has resulted in unprecedented increases in sickness, death, economic disruption, and social disturbances globally. However, the virus (SARS-CoV-2) that caused this pandemic is only one of many viruses threatening public health. Consequently, it is important to have effective means of preventing viral transmission and reducing its devastating effects on human and animal health. Although many antivirals are already available, their efficacy is often limited because of factors such as poor solubility, low permeability, poor bioavailability, un-targeted release, adverse side effects, and antiviral resistance. Many of these problems can be overcome using advanced antiviral delivery systems constructed using nanotechnology principles. These delivery systems consist of antivirals loaded into nanoparticles, which may be fabricated from either synthetic or natural materials. Nevertheless, there is increasing emphasis on the development of antiviral delivery systems from natural substances, such as lipids, phospholipids, surfactants, proteins, and polysaccharides, due to health and environmental issues. The composition, morphology, dimensions, and interfacial characteristics of nanoparticles can be manipulated to improve the handling, stability, and potency of antivirals. This article outlines the major classes of antivirals, summarizes the challenges currently limiting their efficacy, and highlights how nanoparticles can be used to overcome these challenges. Recent studies on the application of antiviral nanoparticle-based delivery systems are reviewed and future directions are described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.